1 / 7

CNS Specific Antisense Oligonucleotide Market

CNS-specific antisense oligonucleotides (ASOs) are a class of therapeutic molecules designed to target and modulate gene expression in the central nervous system (CNS). ASOs are short synthetic strands of nucleic acids, typically made up of 18 to 30 nucleotides, that can selectively bind to specific RNA sequences in a sequence-specific manner.

Aarav658
Download Presentation

CNS Specific Antisense Oligonucleotide Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLOBAL CAR T CELL THERAPY MARKET Market Size (2017E) US$ 0.07 BN CAGR (2019–2028) 46.1% Market Size (2028F) US$ 8.5 BN

  2. Segmentation (Scope) By Drug By Indication • Hereditary transthyretin amyloidosis (hATTR) • Approved • Spinal Muscular Atrophy • Patisiran • Huntington’s Disease • Nusinersen • Inotersen • Pipeline • IONIS-HTT Rx (RG6042) © Coherent Market Insights. All Rights Reserved

  3. Key Facts • CNS-specific antisense oligonucleotide (ASO) market is experiencing significant growth due to the rising prevalence of neurological disorders and the increasing demand for targeted therapies. • ASOs are short DNA or RNA molecules designed to specifically bind to messenger RNA (mRNA) and inhibit the production of disease-causing proteins. • The CNS-specific ASO market is driven by the need for effective treatments for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). © Coherent Market Insights. All Rights Reserved

  4. Market Purview • The CNS-specific antisense oligonucleotide (ASO) market is a rapidly growing sector focused on developing targeted therapies for neurological disorders within the central nervous system. • This market involves the development, production, and commercialization of ASOs designed to modulate gene expression and inhibit the production of disease-causing proteins in conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and other neurodegenerative disorders. © Coherent Market Insights. All Rights Reserved

  5. Few Leading Companies Alnylam Pharmaceuticals Inc. Sarepta Therapeutics Inc. Biogen Inc. Ionis Pharmaceuticals Inc. © Coherent Market Insights. All Rights Reserved

  6. Global CNS Specific Antisense Oligonucleotide Market (%), By Region, 2023 32.5% ? ? ? ? North America Europe Apac Latin America Middle East © Coherent Market Insights. All Rights Reserved

More Related